Impact of digital information on managing symptoms and recovery after surgery for gullet or stomach cancer

Impact of feedback from Real-time, electronic symptom monitoring on post-discharge recOvery after Surgery for oEsophago-gastric cancer: a multi-centre randomised controlled trial: the ROSE study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51267295

Enrollment

206

Registered

2024-01-19

Start date

2025-05-29

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophago-gastric cancer Cancer

Interventions

The ROSE study is a multicentre parallel group Randomised Controlled Trial with an internal pilot phase. 206 participants will be randomised from approximately six NHS hospitals in England, in a 1:1 r

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adults aged >=18 years 2. Referred by the hospital multidisciplinary healthcare team for elective oesophagectomy (oesophageal resection) or total/subtotal gastrectomy (gastric resection) for oesophago-gastric cancer

Exclusion criteria

Exclusion criteria: 1. Planned discharge NOT back to their home 2. No access to a personal email account 3. No access to a computer/mobile device or internet at their usual place of residence 4. Unwilling to use electronic information tool/electronic questionnaire system or participate in research 5. Unable to provide written informed consent 6. Insufficient understanding of English to complete questionnaires 7. Participating in other research that would interfere with participation in this study

Design outcomes

Primary

Measure	Time frame
Quality of recovery from surgery measured using the Quality of Recovery questionnaire (QoR-40) over 4 weeks post-randomisation (approximately 4 weeks post-discharge)	—

Secondary

Measure	Time frame
1. Economic impact from the NHS perspective of the electronic information tool compared with usual care within 4 weeks post-hospital discharge 2. Disease-specific symptoms and wellbeing/quality-of-life measured using Functional Assessment of Cancer Therapy Esophageal/Gastric (FACT-E/Ga) questionnaires and general health status (EQ-5D-5L questionnaires) at 4 weeks post-discharge 3. Clinical events (including complications, readmission/reintervention, healthcare contacts) recorded within 4 weeks post-discharge 4. Healthcare resource use recorded within 4 weeks post-discharge	—

Measure

Time frame

1. Economic impact from the NHS perspective of the electronic information tool compared with usual care within 4 weeks post-hospital discharge 2. Disease-specific symptoms and wellbeing/quality-of-life measured using Functional Assessment of Cancer Therapy Esophageal/Gastric (FACT-E/Ga) questionnaires and general health status (EQ-5D-5L questionnaires) at 4 weeks post-discharge 3. Clinical events (including complications, readmission/reintervention, healthcare contacts) recorded within 4 weeks post-discharge 4. Healthcare resource use recorded within 4 weeks post-discharge

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026